A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Michael Unterhalt, Martin Dreyling et al.|Blood|2007Cited by 971
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Neal S. Young, Scott A. Rollins et al.|Blood|2007Cited by 578
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)Georg Lenz, Wolfgang Hiddemann, Martin Dreyling et al.|Journal of Clinical Oncology|2005Cited by 573
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Eva Hoster et al.|The Lancet|2016Cited by 401
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell LymphomaStefan Alig, Ash A. Alizadeh, Charles Macaulay et al.|Journal of Clinical Oncology|2021Cited by 78